¿Ampersand Medical Corp., of Chicago, said it received an initial probe for human papilloma virus (HPV) detection from Invirion Inc., of Frankfurt, Mich. Ampersand plans to use the technology to begin human clinical studies on the probe by the end of next year. Ampersand and Invirion agreed to a licensing agreement in June for Invirion's HPV detection technology.

¿AniGenics Inc., of San Francisco, said it will use the most complete map available of human and cattle genomes to develop new production trait genetic markers in cattle and new drug targets for the human and veterinary markets. The map was developed by researchers from the University of Illinois at Urbana-Champaign and Texas A&M University.

¿Atherogenics Inc., of Alpharetta, Ga., said underwriters for the company's initial public offering have exercised their overallotment option to purchase an additional 900,000 shares of stock, bringing the offering's total proceeds to about $50 million after expenses. Chase H&Q was lead underwriter for the offering. Co-managers were Robertson Stephens; Adams, Harkness & Hill; and A.G. Edwards & Sons.

¿Caliper Technologies Corp., of Mountain View, Calif., said it introduced a new LabChip system for automated nucleic acid separation and analysis. The system, dubbed Automated Microfluidics System 90, automates the sizing, concentration and purity analysis of nucleic acid fragments.

¿Cell Pathways Inc., of Horsham, Pa., said a combination of the anticancer drugs Aptosyn and Taxotere significantly increased survival and reduced the incidence of metastases in a rat model of human non-small-cell lung cancer. These positive effects were significantly better in animals taking both drugs. Results from the preclinical study were presented at the 9th World Conference on Lung Cancer 2000 in Tokyo.

¿ChromaVison Medical Systems Inc., of San Juan Capistrano, said it began development of three new ACIS tests to address a wide variety of cancer types. The new tests are designed to assess whether aggressive or new drug therapies are appropriate for a given patient. ChromaVision estimates the U.S. market for the products to be in excess of $38 million annually.

¿Compugen Ltd., of Tel Aviv, Israel, reached the third milestone in its agreement with Pfizer Global Research and Development, delivering computational capabilities including the identification of predicted genes through clustering and assembly of genomic DNA and cDNA sequences that take into account predicted splice variants. The milestone is a part of a deal that includes access to Compugen's 2D gel analysis software package, Z3; LEADS, the company's advanced genomic discovery platform; and DNA chip design. Compugen completed the first two milestones in May and November 1999.

¿Diamyd Medical AB, of Stockholm, Sweden, said its GAD-based vaccine has entered Phase II studies in GAD antibody-positive, type 2 diabetes patients in Malmo, Sweden. The company said disappointing results for oral insulin reported in the Aug. 12, 2000 issue of The Lancet strengthen its position.

¿ExonHit Therapeutics SA, of Paris, is offering its Safe-Hit predictive toxicology testing service of a fee-for-service basis with a sample turnaround time of 60 days. Clients can send coded samples to ExonHit and will receive a full report, including ranked compounds as well as names of relevant proteins for which encoding mRNAs have been modified as a result of treatment.

¿Geneva Proteomics Inc., of Evanston, Ill., and Bruker Daltronics Inc., of Billerica, Mass., entered an agreement in which Geneva purchased 51 mass spectrometry systems, consumables and support from Bruker. As part of this alliance, the parties will collaborate on research and development in proteomics and will share certain proteomics intellectual property and technology. Bruker is making a strategic equity investment in Geneva of cash and stock.

¿Human Genome Sciences Inc., of Rockville, Md., said it will advance its development program for repifermin (keratinocyte growth factor-2). Results from a Phase IIa trial of repifermin in venous ulcers indicate the drug accelerates healing in chronic venous ulcers. HGS said the 15-center, randomized, double-blind, placebo-controlled trial encourages researchers to perform additional clinical study of the compound.

¿Incyte Genomics Inc., of Palo Alto, Calif. and IBM, of Somers, N.Y., have agreed to include IBM's DiscoveryLink data management software in Incyte's Genomic Knowledge Platform. IBM founded IBM Life Science, a business unit that will invest up to $100 million in bioinformatics, in August. Incyte is the first bioinformatics collaboration for the computing giant. Incyte officials said the new software environment will enable researchers to take a fast track in analyzing complex biological systems, offering single-query analysis of an integrated database of gene sequence, expression, polymorphism and proteomic data.

¿Inkine Pharmaceutical Co., of Blue Bell, Pa., said an article on the evaluation of a delivery system of a sodium phosphate purge appeared in the September issue of Gastrointestinal Endoscopy. In the evaluation, 305 patients undergoing diagnostic colonoscopy answered a questionnaire regarding quality of bowel cleansing.

¿Inspire Pharmaceuticals Inc., of Durham, N.C., and Kirin Brewery Co. Ltd., of Tokyo, agreed to terms in which Kirin's pharmaceutical division will develop and commercialize Inspire's lung-disease diagnostic adjunct product, INS316 Diagnostic, in 21 Asian countries and regions. Inspire will receive an up-front payment in cash and milestone payments based on clinical success and approval. Also, net royalties will be paid to Inspire over the long term. INS316 Diagnostic is an inhaled solution being developed as an adjunct for diagnosing lung disease and/or lung infections.

¿Invitrogen Corp., of San Diego, commercialized MyArray DNA, a customizable service for life science and genomic researchers producing microarrays to study gene expression. The service provides online access to a database of more than 3 million DNA clones. MyArray DNA was developed and will be marketed by Invitrogen's subsidiary, Research Genetics, of Huntsville, Ala.

¿La Jolla Pharmaceutical Co., of San Diego, presented preclinical results which showed its clinical Toleragen candidate, LJP 1082, reduced disease-causing antibodies involved in antibody-mediated thrombosis. Company scientists presented two papers on the results at the 9th International Symposium on Antiphospholipid Antibodies in Tours, France. La Jolla's tolerance technology is designed to stop the production of disease-causing antibodies without suppressing the healthy functions of the immune system.

¿Luminex Corporation Inc., of Austin, Texas, and its collaborator Life Technologies Inc., of Rockville, Md., were granted reinstatement of a grant from the National Institute of Standards and Technology Advanced Technology Program. The three-year, $6.3 million grant will fund 49 percent of Luminex's project costs for development of processes to enable up to 1 million DNA assays to be performed in a single tube on the surface of fluorescently encoded microscopic beads.

¿Maxim Pharmaceuticals Inc., of San Diego, said the September issue of Blood includes publication of a preclinical study demonstrating that the company's lead drug candidate, Maxamine (histamine dihydrochloride), protected critical immune system cells from inhibition by cancer cells recovered from patients with chronic myelogenous leukemia. The study focused on CML cell inhibition of NK cells and T cells.

¿Serono S.A., of Geneva, said the European Commission granted the company Orphan Medicinal Product designation for the recombinant human growth hormone product Serostim, the first such designation the EC has granted under its new regulation on orphan products passed in January.

¿Specialty Laboratories Inc., of Santa Monica, Calif., filed a registration statement with the SEC for an IPO. Merrill Lynch & Co. is acting as lead manager of the offering, with UBS Warburg LLC and U.S. Bancorp Piper Jaffray Inc. as co-managers. Specialty will apply to trade under the symbol SPLB. The company primarily develops and performs esoteric clinical laboratory assays and will use the proceeds from the offering to pay financial obligations, expand research and product development, expand sales and marketing, for other general corporate purposes and funding of potential acquisitions.

¿Synaptic Pharmaceutical Corp., of Paramus, N.J., made available its Universal Function Assay for customers from the pharmaceutical and biotechnology industries. The assay identifies natural ligands for orphan G protein-coupled receptors. Customers can send their orphan GPCRs to Synaptic under a service and license agreement, and Synaptic will screen the GPCRs and identify hits.

¿ZymeTx Inc., of Oklahoma City, put an Influenza Disease Management program of vaccination, surveillance, diagnosis and treatment in place for U.S. athletes competing in the Sydney Olympics this month. The World Health Organization issued a flu warning for Sydney in August.

No Comments